Free Shipping on All Orders $75 Or More!

Your Trusted Brand for Over 35 Years

Health Protocols

  1. Miquel S, Champ C, Day J, et al. Poor cognitive ageing: Vulnerabilities, mechanisms and the impact of nutritional interventions. Ageing Res Rev. 2018;42:40-55.
  2. Knight JN, Y. . Anatomy and physiology of ageing 5: the nervous system. Nursing Times [online]. 2017;113(6):55-58.
  3. Park DC, Festini SB. Theories of Memory and Aging: A Look at the Past and a Glimpse of the Future. The journals of gerontology Series B, Psychological sciences and social sciences. 2017;72(1):82-90.
  4. Anastasiou CA, Yannakoulia M, Kontogianni MD, et al. Mediterranean Lifestyle in Relation to Cognitive Health: Results from the HELIAD Study. Nutrients. 2018;10(10).
  5. Wyss-Coray T. Ageing, neurodegeneration and brain rejuvenation. Nature. 2016;539(7628):180-186.
  6. Phillips C. Lifestyle Modulators of Neuroplasticity: How Physical Activity, Mental Engagement, and Diet Promote Cognitive Health during Aging. Neural plasticity. 2017;2017:3589271.
  7. Steindler DA, Reynolds BA. Perspective: Neuroregenerative Nutrition. Adv Nutr. 2017;8(4):546-557.
  8. Poulose SM, Miller MG, Scott T, Shukitt-Hale B. Nutritional Factors Affecting Adult Neurogenesis and Cognitive Function. Adv Nutr. 2017;8(6):804-811.
  9. Palmer AL, Ousman SS. Astrocytes and Aging. Frontiers in aging neuroscience. 2018;10:337.
  10. Liu H, Yang Y, Xia Y, et al. Aging of cerebral white matter. Ageing Res Rev. 2017;34:64-76.
  11. Lopez-Valdes HE, Martinez-Coria H. The Role of Neuroinflammation in Age-Related Dementias. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion. 2016;68(1):40-48.
  12. Smith LK, White CW, 3rd, Villeda SA. The systemic environment: at the interface of aging and adult neurogenesis. Cell and tissue research. 2018;371(1):105-113.
  13. Raz N, Daugherty AM. Pathways to Brain Aging and Their Modifiers: Free-Radical-Induced Energetic and Neural Decline in Senescence (FRIENDS) Model - A Mini-Review. Gerontology. 2018;64(1):49-57.
  14. Yang T, Sun Y, Lu Z, Leak RK, Zhang F. The impact of cerebrovascular aging on vascular cognitive impairment and dementia. Ageing Res Rev. 2017;34:15-29.
  15. Safaiyan S, Kannaiyan N, Snaidero N, et al. Age-related myelin degradation burdens the clearance function of microglia during aging. Nat Neurosci. 2016;19(8):995-998.
  16. Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review. Jama. 2014;312(23):2551-2561.
  17. Hugo J, Ganguli M. Dementia and cognitive impairment: epidemiology, diagnosis, and treatment. Clin Geriatr Med. 2014;30(3):421-442.
  18. Allan CL, Behrman S, Ebmeier KP, Valkanova V. Diagnosing early cognitive decline-When, how and for whom? Maturitas. 2017;96:103-108.
  19. Langa KM, Larson EB, Crimmins EM, et al. A Comparison of the Prevalence of Dementia in the United States in 2000 and 2012. JAMA internal medicine. 2017;177(1):51-58.
  20. Cheng YW, Chen TF, Chiu MJ. From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution. Neuropsychiatr Dis Treat. 2017;13:491-498.
  21. Michel JP. Is It Possible to Delay or Prevent Age-Related Cognitive Decline? Korean journal of family medicine. 2016;37(5):263-266.
  22. Vicario A, Cerezo GH. At the Heart of Brain Disorders - Preventing Cognitive Decline and Dementia. European cardiology. 2015;10(1):60-63.
  23. Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. Alzheimer's & Dementia. 2015;11(6):718-726.
  24. Deckers K, Schievink SHJ, Rodriquez MMF, et al. Coronary heart disease and risk for cognitive impairment or dementia: Systematic review and meta-analysis. PLoS One. 2017;12(9):e0184244.
  25. Zhao C, Noble JM, Marder K, Hartman JS, Gu Y, Scarmeas N. Dietary Patterns, Physical Activity, Sleep, and Risk for Dementia and Cognitive Decline. Current nutrition reports. 2018;7(4):335-345.
  26. Leng Y, McEvoy CT, Allen IE, Yaffe K. Association of Sleep-Disordered Breathing With Cognitive Function and Risk of Cognitive Impairment: A Systematic Review and Meta-analysis. JAMA Neurol. 2017;74(10):1237-1245.
  27. Smith AD, Refsum H, Bottiglieri T, et al. Homocysteine and Dementia: An International Consensus Statement. J Alzheimers Dis. 2018;62(2):561-570.
  28. Karri V, Schuhmacher M, Kumar V. Heavy metals (Pb, Cd, As and MeHg) as risk factors for cognitive dysfunction: A general review of metal mixture mechanism in brain. Environmental toxicology and pharmacology. 2016;48:203-213.
  29. Brandt J, Leong C. Benzodiazepines and Z-Drugs: An Updated Review of Major Adverse Outcomes Reported on in Epidemiologic Research. Drugs in R&D. 2017;17(4):493-507.
  30. Picton JD, Marino AB, Nealy KL. Benzodiazepine use and cognitive decline in the elderly. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2018;75(1):e6-e12.
  31. Gray SL, Hanlon JT. Anticholinergic medication use and dementia: latest evidence and clinical implications. Therapeutic advances in drug safety. 2016;7(5):217-224.
  32. Colangelo A, Cirillo G, Alberghina L, Papa M, Westerhoff H. Neural plasticity and adult neurogenesis: the deep biology perspective. Neural Regeneration Research. 2019;14(2):201-205.
  33. de Lucia C, Murphy T, Thuret S. Emerging Molecular Pathways Governing Dietary Regulation of Neural Stem Cells during Aging. Front Physiol. 2017;8:17.
  34. Numakawa T, Odaka H, Adachi N. Actions of Brain-Derived Neurotrophin Factor in the Neurogenesis and Neuronal Function, and Its Involvement in the Pathophysiology of Brain Diseases. International journal of molecular sciences. 2018;19(11).
  35. Rivera A, Vanzuli I, Arellano JJ, Butt A. Decreased Regenerative Capacity of Oligodendrocyte Progenitor Cells (NG2-Glia) in the Ageing Brain: A Vicious Cycle of Synaptic Dysfunction, Myelin Loss and Neuronal Disruption? Current Alzheimer research. 2016;13(4):413-418.
  36. Apple DM, Solano-Fonseca R, Kokovay E. Neurogenesis in the aging brain. Biochemical pharmacology. 2017;141:77-85.
  37. Wang Y, Ji X, Leak RK, Chen F, Cao G. Stem cell therapies in age-related neurodegenerative diseases and stroke. Ageing Res Rev. 2017;34:39-50.
  38. Nivet E. Modifiers of Neural Stem Cells and Aging: Pulling the Trigger of a Neurogenic Decline. Current Stem Cell Reports. 2016;2(3):273-281.
  39. Brainard J, Gobel M, Bartels K, Scott B, Koeppen M, Eckle T. Circadian rhythms in anesthesia and critical care medicine: potential importance of circadian disruptions. Seminars in cardiothoracic and vascular anesthesia. 2015;19(1):49-60.
  40. Krishnan HC, Lyons LC. Synchrony and desynchrony in circadian clocks: impacts on learning and memory. Learning & memory (Cold Spring Harbor, NY). 2015;22(9):426-437.
  41. Pace-Schott EF, Spencer RM. Sleep-dependent memory consolidation in healthy aging and mild cognitive impairment. Curr Top Behav Neurosci. 2015;25:307-330.
  42. Terzibasi-Tozzini E, Martinez-Nicolas A, Lucas-Sanchez A. The clock is ticking. Ageing of the circadian system: From physiology to cell cycle. Seminars in cell & developmental biology. 2017;70:164-176.
  43. Toth P, Tarantini S, Csiszar A, Ungvari Z. Functional vascular contributions to cognitive impairment and dementia: mechanisms and consequences of cerebral autoregulatory dysfunction, endothelial impairment, and neurovascular uncoupling in aging. American journal of physiology Heart and circulatory physiology. 2017;312(1):H1-h20.
  44. Tarantini S, Tran CHT, Gordon GR, Ungvari Z, Csiszar A. Impaired neurovascular coupling in aging and Alzheimer's disease: Contribution of astrocyte dysfunction and endothelial impairment to cognitive decline. Exp Gerontol. 2017;94:52-58.
  45. Martinez-Ramirez S, Greenberg SM, Viswanathan A. Cerebral microbleeds: overview and implications in cognitive impairment. Alzheimer's Research & Therapy. 2014;6(3):33.
  46. De Luca C, Colangelo AM, Alberghina L, Papa M. Neuro-Immune Hemostasis: Homeostasis and Diseases in the Central Nervous System. Frontiers in cellular neuroscience. 2018;12:459.
  47. Yin F, Sancheti H, Patil I, Cadenas E. Energy metabolism and inflammation in brain aging and Alzheimer's disease. Free radical biology & medicine. 2016;100:108-122.
  48. Grizzanti J, Lee HG, Camins A, Pallas M, Casadesus G. The therapeutic potential of metabolic hormones in the treatment of age-related cognitive decline and Alzheimer's disease. Nutr Res. 2016;36(12):1305-1315.
  49. Noble EE, Hsu TM, Kanoski SE. Gut to Brain Dysbiosis: Mechanisms Linking Western Diet Consumption, the Microbiome, and Cognitive Impairment. Frontiers in behavioral neuroscience. 2017;11:9.
  50. Grimm A, Eckert A. Brain aging and neurodegeneration: from a mitochondrial point of view. Journal of neurochemistry. 2017;143(4):418-431.
  51. Khacho M, Clark A, Svoboda DS, et al. Mitochondrial dysfunction underlies cognitive defects as a result of neural stem cell depletion and impaired neurogenesis. Human molecular genetics. 2017;26(17):3327-3341.
  52. Sripetchwandee J, Chattipakorn N, Chattipakorn SC. Links Between Obesity-Induced Brain Insulin Resistance, Brain Mitochondrial Dysfunction, and Dementia. Frontiers in endocrinology. 2018;9:496.
  53. Salameh TS, Rhea EM, Banks WA, Hanson AJ. Insulin resistance, dyslipidemia, and apolipoprotein E interactions as mechanisms in cognitive impairment and Alzheimer's disease. Experimental biology and medicine (Maywood, NJ). 2016;241(15):1676-1683.
  54. Assuncao N, Sudo FK, Drummond C, de Felice FG, Mattos P. Metabolic Syndrome and cognitive decline in the elderly: A systematic review. PLoS One. 2018;13(3):e0194990.
  55. Moon JH. Endocrine Risk Factors for Cognitive Impairment. Endocrinology and metabolism (Seoul, Korea). 2016;31(2):185-192.
  56. Walker JM, Harrison FE. Shared Neuropathological Characteristics of Obesity, Type 2 Diabetes and Alzheimer's Disease: Impacts on Cognitive Decline. Nutrients. 2015;7(9):7332-7357.
  57. Bae CS, Song J. The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain. International journal of molecular sciences. 2017;18(11).
  58. McInnes K, Friesen CL, MacKenzie DE, Westwood DA, Boe SG. Mild Traumatic Brain Injury (mTBI) and chronic cognitive impairment: A scoping review. PLoS One. 2017;12(4):e0174847.
  59. McAllister T, McCrea M. Long-Term Cognitive and Neuropsychiatric Consequences of Repetitive Concussion and Head-Impact Exposure. Journal of athletic training. 2017;52(3):309-317.
  60. Fehily B, Fitzgerald M. Repeated Mild Traumatic Brain Injury: Potential Mechanisms of Damage. Cell transplantation. 2017;26(7):1131-1155.
  61. Giza CC, Hovda DA. The new neurometabolic cascade of concussion. Neurosurgery. 2014;75 Suppl 4:S24-33.
  62. Oehr L, Anderson J. Diffusion-Tensor Imaging Findings and Cognitive Function Following Hospitalized Mixed-Mechanism Mild Traumatic Brain Injury: A Systematic Review and Meta-Analysis. Archives of physical medicine and rehabilitation. 2017;98(11):2308-2319.
  63. Broglio SP, Eckner JT, Paulson HL, Kutcher JS. Cognitive decline and aging: the role of concussive and subconcussive impacts. Exercise and sport sciences reviews. 2012;40(3):138-144.
  64. NIH. National Institues of Health: National Institute on Aging: What happens to the brain in Alzheimer's disease? Available at Last updated 05/16/2017. Accessed 01/09/2019. 2017.
  65. Laurent C, Buee L, Blum D. Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies? Biomedical journal. 2018;41(1):21-33.
  66. Chalermpalanupap T, Weinshenker D, Rorabaugh JM. Down but Not Out: The Consequences of Pretangle Tau in the Locus Coeruleus. Neural plasticity. 2017;2017:7829507.
  67. Mufson EJ, Ikonomovic MD, Counts SE, et al. Molecular and cellular pathophysiology of preclinical Alzheimer's disease. Behavioural brain research. 2016;311:54-69.
  68. Colijn MA, Grossberg GT. Amyloid and Tau Biomarkers in Subjective Cognitive Impairment. J Alzheimers Dis. 2015;47(1):1-8.
  69. Villemagne VL, Dore V, Bourgeat P, et al. Abeta-amyloid and Tau Imaging in Dementia. Seminars in nuclear medicine. 2017;47(1):75-88.
  70. Mielke MM, Hagen CE, Wennberg AMV, et al. Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging. JAMA Neurol. 2017;74(9):1073-1080.
  71. Guerrero-Munoz MJ, Gerson J, Castillo-Carranza DL. Tau Oligomers: The Toxic Player at Synapses in Alzheimer's Disease. Frontiers in cellular neuroscience. 2015;9:464.
  72. Cui D, Xu X. DNA Methyltransferases, DNA Methylation, and Age-Associated Cognitive Function. International journal of molecular sciences. 2018;19(5).
  73. Deibel SH, Zelinski EL, Keeley RJ, Kovalchuk O, McDonald RJ. Epigenetic alterations in the suprachiasmatic nucleus and hippocampus contribute to age-related cognitive decline. Oncotarget. 2015;6(27):23181-23203.
  74. Daulatzai MA. "Boomerang Neuropathology" of Late-Onset Alzheimer's Disease is Shrouded in Harmful "BDDS": Breathing, Diet, Drinking, and Sleep During Aging. Neurotoxicity research. 2015;28(1):55-93.
  75. Moretti R, Caruso P. The Controversial Role of Homocysteine in Neurology: From Labs to Clinical Practice. International journal of molecular sciences. 2019;20(1).
  76. Price BR, Wilcock DM, Weekman EM. Hyperhomocysteinemia as a Risk Factor for Vascular Contributions to Cognitive Impairment and Dementia. Frontiers in aging neuroscience. 2018;10:350.
  77. Mikkelsen K, Stojanovska L, Tangalakis K, Bosevski M, Apostolopoulos V. Cognitive decline: A vitamin B perspective. Maturitas. 2016;93:108-113.
  78. Merlini M, Rafalski VA, Rios Coronado PE, et al. Fibrinogen Induces Microglia-Mediated Spine Elimination and Cognitive Impairment in an Alzheimer's Disease Model. Neuron. 2019.
  79. Marioni RE, Stewart MC, Murray GD, et al. Peripheral levels of fibrinogen, C-reactive protein, and plasma viscosity predict future cognitive decline in individuals without dementia. Psychosomatic medicine. 2009;71(8):901-906.
  80. Marioni RE, Deary IJ, Murray GD, et al. Genetic associations between fibrinogen and cognitive performance in three Scottish cohorts. Behav Genet. 2011;41(5):691-699.
  81. Pedersen A, Stanne TM, Redfors P, et al. Fibrinogen concentrations predict long-term cognitive outcome in young ischemic stroke patients. Research and practice in thrombosis and haemostasis. 2018;2(2):339-346.
  82. Ebner NC, Kamin H, Diaz V, Cohen RA, MacDonald K. Hormones as "difference makers" in cognitive and socioemotional aging processes. Frontiers in psychology. 2014;5:1595.
  83. Lejri I, Grimm A, Eckert A. Mitochondria, Estrogen and Female Brain Aging. Frontiers in aging neuroscience. 2018;10:124.
  84. Hara Y, Waters EM, McEwen BS, Morrison JH. Estrogen Effects on Cognitive and Synaptic Health Over the Lifecourse. Physiol Rev. 2015;95(3):785-807.
  85. Dumas JA. Strategies for Preventing Cognitive Decline in Healthy Older Adults. Can J Psychiatry. 2017;62(11):754-760.
  86. Yeap BB. Hormonal changes and their impact on cognition and mental health of ageing men. Maturitas. 2014;79(2):227-235.
  87. Hsu B, Cumming RG, Waite LM, et al. Longitudinal Relationships between Reproductive Hormones and Cognitive Decline in Older Men: The Concord Health and Ageing in Men Project. J Clin Endocrinol Metab. 2015;100(6):2223-2230.
  88. Hogervorst E. Effects of gonadal hormones on cognitive behaviour in elderly men and women. J Neuroendocrinol. 2013;25(11):1182-1195.
  89. Hogervorst E. Prevention of dementia with sex hormones: a focus on testosterone and cognition in women. Minerva Med. 2012;103(5):353-359.
  90. Tortosa-Martinez J, Manchado C, Cortell-Tormo JM, Chulvi-Medrano I. Exercise, the diurnal cycle of cortisol and cognitive impairment in older adults. Neurobiology of stress. 2018;9:40-47.
  91. Russell-Williams J, Jaroudi W, Perich T, Hoscheidt S, El Haj M, Moustafa AA. Mindfulness and meditation: treating cognitive impairment and reducing stress in dementia. Rev Neurosci. 2018;29(7):791-804.
  92. Samaras N, Papadopoulou MA, Samaras D, Ongaro F. Off-label use of hormones as an antiaging strategy: a review. Clinical interventions in aging. 2014;9:1175-1186.
  93. Maggio M, De Vita F, Fisichella A, et al. DHEA and cognitive function in the elderly. J Steroid Biochem Mol Biol. 2015;145:281-292.
  94. de Menezes KJ, Peixoto C, Nardi AE, Carta MG, Machado S, Veras AB. Dehydroepiandrosterone, Its Sulfate and Cognitive Functions. Clinical practice and epidemiology in mental health : CP & EMH. 2016;12:24-37.
  95. Powrie YSL, Smith C. Central intracrine DHEA synthesis in ageing-related neuroinflammation and neurodegeneration: therapeutic potential? Journal of neuroinflammation. 2018;15(1):289.
  96. Jimenez-Rubio G, Herrera-Perez JJ, Hernandez-Hernandez OT, Martinez-Mota L. Relationship between androgen deficiency and memory impairment in aging and Alzheimer’s disease. Actas espanolas de psiquiatria. 2017;45(5):227-247.
  97. Kotekar N, Shenkar A, Nagaraj R. Postoperative cognitive dysfunction - current preventive strategies. Clin Interv Aging. 2018;13:2267-2273.
  98. Needham MJ, Webb CE, Bryden DC. Postoperative cognitive dysfunction and dementia: what we need to know and do. British journal of anaesthesia. 2017;119(suppl_1):i115-i125.
  99. Kant IMJ, de Bresser J, van Montfort SJT, Slooter AJC, Hendrikse J. MRI Markers of Neurodegenerative and Neurovascular Changes in Relation to Postoperative Delirium and Postoperative Cognitive Decline. Am J Geriatr Psychiatry. 2017;25(10):1048-1061.
  100. Liu Y, Yin Y. Emerging Roles of Immune Cells in Postoperative Cognitive Dysfunction. Mediators of inflammation. 2018;2018:6215350.
  101. Cascella M, Bimonte S. The role of general anesthetics and the mechanisms of hippocampal and extra-hippocampal dysfunctions in the genesis of postoperative cognitive dysfunction. Neural Regen Res. 2017;12(11):1780-1785.
  102. Luo A, Yan J, Tang X, Zhao Y, Zhou B, Li S. Postoperative cognitive dysfunction in the aged: the collision of neuroinflammaging with perioperative neuroinflammation. Inflammopharmacol. 2019.
  103. Safavynia SA, Goldstein PA. The Role of Neuroinflammation in Postoperative Cognitive Dysfunction: Moving From Hypothesis to Treatment. Frontiers in psychiatry. 2018;9:752.
  104. Brown Ct, Deiner S. Perioperative cognitive protection. British journal of anaesthesia. 2016;117(suppl 3):iii52-iii61.
  105. Hernandorena I, Duron E, Vidal JS, Hanon O. Treatment options and considerations for hypertensive patients to prevent dementia. Expert opinion on pharmacotherapy. 2017;18(10):989-1000.
  106. Tadic M, Cuspidi C, Hering D. Hypertension and cognitive dysfunction in elderly: blood pressure management for this global burden. BMC cardiovascular disorders. 2016;16(1):208.
  107. Chu CS, Tseng PT, Stubbs B, et al. Use of statins and the risk of dementia and mild cognitive impairment: A systematic review and meta-analysis. Sci Rep. 2018;8(1):5804.
  108. Schultz BG, Patten DK, Berlau DJ. The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. Translational neurodegeneration. 2018;7:5.
  109. Bosch J, O'Donnell M, Swaminathan B, et al. Effects of blood pressure and lipid lowering on cognition. Results from the HOPE-3 study. 2019:10.1212/WNL.0000000000007174.
  110. Ong KL, Morris MJ, McClelland RL, et al. Relationship of Lipids and Lipid-Lowering Medications With Cognitive Function: The Multi-Ethnic Study of Atherosclerosis. American journal of epidemiology. 2018;187(4):767-776.
  111. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. The Cochrane database of systematic reviews. 2016(1):Cd003160.
  112. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623-1630.
  113. Group HPSC. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
  114. Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? The American journal of cardiology. 2006;97(2a):33a-41a.
  115. Karakaya T, Fußer F, Schröder J, Pantel J. Pharmacological Treatment of Mild Cognitive Impairment as a Prodromal Syndrome of Alzheimer´s Disease. Curr Neuropharmacol. 2013;11(1):102-108.
  116. Farlow MR. Treatment of mild cognitive impairment (MCI). Current Alzheimer research. 2009;6(4):362-367.
  117. Tripathi A, Paliwal P, Krishnamurthy S. Piracetam Attenuates LPS-Induced Neuroinflammation and Cognitive Impairment in Rats. Cellular and molecular neurobiology. 2017;37(8):1373-1386.
  118. Sanchez PE, Zhu L, Verret L, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A. 2012;109(42):E2895-2903.
  119. Stockburger C, Kurz C, Koch KA, Eckert SH, Leuner K, Muller WE. Improvement of mitochondrial function and dynamics by the metabolic enhancer piracetam. Biochem Soc Trans. 2013;41(5):1331-1334.
  120. Bakker A, Krauss GL, Albert MS, et al. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron. 2012;74(3):467-474.
  121. Tariska P, Paksy A. [Cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia]. Orvosi hetilap. 2000;141(22):1189-1193.
  122. Giannopoulos PF, Chiu J, Pratico D. Learning Impairments, Memory Deficits, and Neuropathology in Aged Tau Transgenic Mice Are Dependent on Leukotrienes Biosynthesis: Role of the cdk5 Kinase Pathway. Molecular neurobiology. 2018.
  123. Giannopoulos PF, Chiu J, Pratico D. Antileukotriene therapy by reducing tau phosphorylation improves synaptic integrity and cognition of P301S transgenic mice. Aging Cell. 2018;17(3):e12759.
  124. Chu J, Li JG, Pratico D. Zileuton improves memory deficits, amyloid and tau pathology in a mouse model of Alzheimer's disease with plaques and tangles. PLoS One. 2013;8(8):e70991.
  125. Di Meco A, Lauretti E, Vagnozzi AN, Pratico D. Zileuton restores memory impairments and reverses amyloid and tau pathology in aged Alzheimer's disease mice. Neurobiol Aging. 2014;35(11):2458-2464.
  126. Shi SS, Yang WZ, Tu XK, Wang CH, Chen CM, Chen Y. 5-Lipoxygenase inhibitor zileuton inhibits neuronal apoptosis following focal cerebral ischemia. Inflammation. 2013;36(6):1209-1217.
  127. Silva BC, de Miranda AS, Rodrigues FG, et al. The 5-lipoxygenase (5-LOX) Inhibitor Zileuton Reduces Inflammation and Infarct Size with Improvement in Neurological Outcome Following Cerebral Ischemia. Curr Neurovasc Res. 2015;12(4):398-403.
  128. Tu XK, Zhang HB, Shi SS, et al. 5-LOX Inhibitor Zileuton Reduces Inflammatory Reaction and Ischemic Brain Damage Through the Activation of PI3K/Akt Signaling Pathway. Neurochem Res. 2016;41(10):2779-2787.
  129. Rouy JM, Douillon AM, Compan B, Wolmark Y. Ergoloid mesylates ('Hydergine') in the treatment of mental deterioration in the elderly: a 6-month double-blind, placebo-controlled trial. Current medical research and opinion. 1989;11(6):380-389.
  130. van Loveren-Huyben CM, Engelaar HF, Hermans MB, van der Bom JA, Leering C, Munnichs JM. Double-blind clinical and psychologic study of ergoloid mesylates (Hydergine) in subjects with senile mental deterioration. J Am Geriatr Soc. 1984;32(8):584-588.
  131. Wadworth AN, Chrisp P. Co-dergocrine mesylate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive decline. Drugs Aging. 1992;2(3):153-173.
  132. Sozmen EY, Kanit L, Kutay FZ, Hariri NI. Possible supportive effects of co-dergocrine mesylate on antioxidant enzyme systems in aged rat brain. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 1998;8(1):13-16.
  133. Miklya I. The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015). Molecular psychiatry. 2016;21(11):1499-1503.
  134. Bettini R, Gorini M. [Effectiveness and tolerability of selegiline in the treatment of pathological cerebral involutions]. Clin Ter. 2002;153(6):377-380.
  135. Goverdhan P, Sravanthi A, Mamatha T. Neuroprotective effects of meloxicam and selegiline in scopolamine-induced cognitive impairment and oxidative stress. International journal of Alzheimer's disease. 2012;2012:974013.
  136. Unal I, Gursoy-Ozdemir Y, Bolay H, Soylemezoglu F, Saribas O, Dalkara T. Chronic daily administration of selegiline and EGb 761 increases brain's resistance to ischemia in mice. Brain research. 2001;917(2):174-181.
  137. Kiray M, Bagriyanik HA, Pekcetin C, Ergur BU, Uysal N. Protective effects of deprenyl in transient cerebral ischemia in rats. The Chinese journal of physiology. 2008;51(5):275-281.
  138. Kiray M, Bagriyanik HA, Pekcetin C, et al. Deprenyl and the relationship between its effects on spatial memory, oxidant stress and hippocampal neurons in aged male rats. Physiological research / Academia Scientiarum Bohemoslovaca. 2006;55(2):205-212.
  139. Marcer D, Hopkins SM. The differential effects of meclofenoxate on memory loss in the elderly. Age Ageing. 1977;6(2):123-131.
  140. Nehru B, Bhalla P, Garg A. Evidence for centrophenoxine as a protective drug in aluminium induced behavioral and biochemical alteration in rat brain. Molecular and cellular biochemistry. 2006;290(1-2):33-42.
  141. Voronina TA, Garibova TL, Trofimov SS, Sopyev Zh A, Petkov VD, Lazarova MB. Comparative studies on the influence of ONK (N(5-hydroxynicotinoil) glutamic acid), piracetam and meclofenoxate on the learning- and memory-impairing effect of scopolamine, clonidine, and methergoline. Acta physiologica et pharmacologica Bulgarica. 1991;17(4):8-16.
  142. Liao Y, Wang R, Tang XC. Centrophenoxine improves chronic cerebral ischemia induced cognitive deficit and neuronal degeneration in rats. Acta Pharmacol Sin. 2004;25(12):1590-1596.
  143. Klimova B, Valis M. Nutritional Interventions as Beneficial Strategies to Delay Cognitive Decline in Healthy Older Individuals. Nutrients. 2018;10(7).
  144. Chieffi S, Messina G, Villano I, et al. Neuroprotective Effects of Physical Activity: Evidence from Human and Animal Studies. Frontiers in neurology. 2017;8:188.
  145. Northey JM, Cherbuin N, Pumpa KL, Smee DJ, Rattray B. Exercise interventions for cognitive function in adults older than 50: a systematic review with meta-analysis. British journal of sports medicine. 2018;52(3):154-160.
  146. Sexton BP, Taylor NF. To sit or not to sit? A systematic review and meta-analysis of seated exercise for older adults. Australasian journal on ageing. 2018.
  147. Cheng ST. Cognitive Reserve and the Prevention of Dementia: the Role of Physical and Cognitive Activities. Curr Psychiatry Rep. 2016;18(9):85.
  148. Thow ME, Summers MJ, Saunders NL, Summers JJ, Ritchie K, Vickers JC. Further education improves cognitive reserve and triggers improvement in selective cognitive functions in older adults: The Tasmanian Healthy Brain Project. Alzheimer's & dementia (Amsterdam, Netherlands). 2018;10:22-30.
  149. Antoniou M, Wright SM. Uncovering the Mechanisms Responsible for Why Language Learning May Promote Healthy Cognitive Aging. Frontiers in psychology. 2017;8:2217.
  150. Roman-Caballero R, Arnedo M, Trivino M, Lupianez J. Musical practice as an enhancer of cognitive function in healthy aging - A systematic review and meta-analysis. PLoS One. 2018;13(11):e0207957.
  151. Fissler P, Kuster OC, Laptinskaya D, Loy LS, von Arnim CAF, Kolassa IT. Jigsaw Puzzling Taps Multiple Cognitive Abilities and Is a Potential Protective Factor for Cognitive Aging. Frontiers in aging neuroscience. 2018;10:299.
  152. Pillai JA, Hall CB, Dickson DW, Buschke H, Lipton RB, Verghese J. Association of crossword puzzle participation with memory decline in persons who develop dementia. Journal of the International Neuropsychological Society : JINS. 2011;17(6):1006-1013.
  153. Ferreira N, Owen A, Mohan A, Corbett A, Ballard C. Associations between cognitively stimulating leisure activities, cognitive function and age-related cognitive decline. International journal of geriatric psychiatry. 2015;30(4):422-430.
  154. Litwin H, Schwartz E, Damri N. Cognitively Stimulating Leisure Activity and Subsequent Cognitive Function: A SHARE-based Analysis. The Gerontologist. 2017;57(5):940-948.
  155. Howard EP, Morris JN, Steel K, et al. Short-Term Lifestyle Strategies for Sustaining Cognitive Status. Biomed Res Int. 2016;2016:7405748.
  156. Lee GJ, Bang HJ, Lee KM, et al. A comparison of the effects between 2 computerized cognitive training programs, Bettercog and COMCOG, on elderly patients with MCI and mild dementia: A single-blind randomized controlled study. Medicine. 2018;97(45):e13007.
  157. Chetelat G, Lutz A, Arenaza-Urquijo E, Collette F, Klimecki O, Marchant N. Why could meditation practice help promote mental health and well-being in aging? Alzheimers Res Ther. 2018;10(1):57.
  158. Sperduti M, Makowski D, Blonde P, Piolino P. Meditation and successful aging: can meditative practices counteract age-related cognitive decline? Geriatrie et psychologie neuropsychiatrie du vieillissement. 2017;15(2):205-213.
  159. Villemure C, Ceko M, Cotton VA, Bushnell MC. Neuroprotective effects of yoga practice: age-, experience-, and frequency-dependent plasticity. Frontiers in human neuroscience. 2015;9:281.
  160. Prakash R, Rastogi P, Dubey I, Abhishek P, Chaudhury S, Small BJ. Long-term concentrative meditation and cognitive performance among older adults. Neuropsychology, development, and cognition Section B, Aging, neuropsychology and cognition. 2012;19(4):479-494.
  161. Luders E, Cherbuin N, Kurth F. Forever Young(er): potential age-defying effects of long-term meditation on gray matter atrophy. Frontiers in psychology. 2014;5:1551.
  162. Gard T, Taquet M, Dixit R, et al. Fluid intelligence and brain functional organization in aging yoga and meditation practitioners. Frontiers in aging neuroscience. 2014;6:76.
  163. Berk L, van Boxtel M, van Os J. Can mindfulness-based interventions influence cognitive functioning in older adults? A review and considerations for future research. Aging & mental health. 2017;21(11):1113-1120.
  164. Gard T, Holzel BK, Lazar SW. The potential effects of meditation on age-related cognitive decline: a systematic review. Ann N Y Acad Sci. 2014;1307:89-103.
  165. Laird KT, Paholpak P, Roman M, Rahi B, Lavretsky H. Mind-Body Therapies for Late-Life Mental and Cognitive Health. Curr Psychiatry Rep. 2018;20(1):2.
  166. Gothe NP, Kramer AF, McAuley E. Hatha Yoga Practice Improves Attention and Processing Speed in Older Adults: Results from an 8-Week Randomized Control Trial. Journal of alternative and complementary medicine (New York, NY). 2017;23(1):35-40.
  167. Dause TJ, Kirby ED. Aging gracefully: social engagement joins exercise and enrichment as a key lifestyle factor in resistance to age-related cognitive decline. Neural Regen Res. 2019;14(1):39-42.
  168. Pillemer SC, Holtzer R. The differential relationships of dimensions of perceived social support with cognitive function among older adults. Aging & mental health. 2016;20(7):727-735.
  169. Parisi JM, Roberts L, Szanton SL, Hodgson NA, Gitlin LN. Valued Activities among Individuals with and without Cognitive Impairments: Findings from the National Health and Aging Trends Study. The Gerontologist. 2017;57(2):309-318.
  170. Hughes TF, Flatt JD, Fu B, Chang CC, Ganguli M. Engagement in social activities and progression from mild to severe cognitive impairment: the MYHAT study. International psychogeriatrics. 2013;25(4):587-595.
  171. Small BJ, Dixon RA, McArdle JJ, Grimm KJ. Do changes in lifestyle engagement moderate cognitive decline in normal aging? Evidence from the Victoria Longitudinal Study. Neuropsychology. 2012;26(2):144-155.
  172. Yates JA, Clare L, Woods RT. "You've got a friend in me": can social networks mediate the relationship between mood and MCI? BMC geriatrics. 2017;17(1):144.
  173. Lee Y, Jean Yeung WJ. Gender matters: Productive social engagement and the subsequent cognitive changes among older adults. Social science & medicine (1982). 2018.
  174. Saint Martin M, Sforza E, Barthelemy JC, et al. Long-lasting active lifestyle and successful cognitive aging in a healthy elderly population: The PROOF cohort. Revue neurologique. 2017;173(10):637-644.
  175. Park S, Kwon E, Lee H. Life Course Trajectories of Later-Life Cognitive Functions: Does Social Engagement in Old Age Matter? International journal of environmental research and public health. 2017;14(4).
  176. Haslam C, Cruwys T, Haslam SA. "The we's have it": evidence for the distinctive benefits of group engagement in enhancing cognitive health in aging. Social science & medicine (1982). 2014;120:57-66.
  177. Roberts RO, Cha RH, Mielke MM, et al. Risk and protective factors for cognitive impairment in persons aged 85 years and older. Neurology. 2015;84(18):1854-1861.
  178. Trost Bobic T, Secic A, Zavoreo I, et al. The Impact of Sleep Deprivation on the Brain. Acta Clin Croat. 2016;55(3):469-473.
  179. Tsapanou A, Vlachos GS, Cosentino S, et al. Sleep and subjective cognitive decline in cognitively healthy elderly: Results from two cohorts. J Sleep Res. 2018.
  180. Dzierzewski JM, Dautovich N, Ravyts S. Sleep and Cognition in Older Adults. Sleep medicine clinics. 2018;13(1):93-106.
  181. Wennberg AMV, Wu MN, Rosenberg PB, Spira AP. Sleep Disturbance, Cognitive Decline, and Dementia: A Review. Seminars in neurology. 2017;37(4):395-406.
  182. Atienza M, Ziontz J, Cantero JL. Low-grade inflammation in the relationship between sleep disruption, dysfunctional adiposity, and cognitive decline in aging. Sleep medicine reviews. 2018;42:171-183.
  183. Akers KG, Cherasse Y, Fujita Y, Srinivasan S, Sakurai T, Sakaguchi M. Concise Review: Regulatory Influence of Sleep and Epigenetics on Adult Hippocampal Neurogenesis and Cognitive and Emotional Function. Stem cells (Dayton, Ohio). 2018;36(7):969-976.
  184. Wu L, Sun D, Tan Y. A systematic review and dose-response meta-analysis of sleep duration and the occurrence of cognitive disorders. Sleep & breathing = Schlaf & Atmung. 2018;22(3):805-814.
  185. Liang Y, Qu LB, Liu H. Non-linear associations between sleep duration and the risks of mild cognitive impairment/dementia and cognitive decline: a dose-response meta-analysis of observational studies. Aging clinical and experimental research. 2018.
  186. Ho ECM, Siu AMH. Occupational Therapy Practice in Sleep Management: A Review of Conceptual Models and Research Evidence. Occupational therapy international. 2018;2018:8637498.
  187. Gutman SA, Gregory KA, Sadlier-Brown MM, et al. Comparative Effectiveness of Three Occupational Therapy Sleep Interventions: A Randomized Controlled Study. OTJR : occupation, participation and health. 2017;37(1):5-13.
  188. Bucks RS, Olaithe M, Rosenzweig I, Morrell MJ. Reviewing the relationship between OSA and cognition: Where do we go from here? Respirology (Carlton, Vic). 2017;22(7):1253-1261.
  189. Ayas NT, Taylor CM, Laher I. Cardiovascular consequences of obstructive sleep apnea. Current opinion in cardiology. 2016;31(6):599-605.
  190. Floras JS. Sleep Apnea and Cardiovascular Disease: An Enigmatic Risk Factor. Circ Res. 2018;122(12):1741-1764.
  191. Chowdhuri S, Patel P, Badr MS. Apnea in Older Adults. Sleep medicine clinics. 2018;13(1):21-37.
  192. Zhu X, Zhao Y. Sleep-disordered breathing and the risk of cognitive decline: a meta-analysis of 19,940 participants. Sleep & breathing = Schlaf & Atmung. 2018;22(1):165-173.
  193. Hobzova M, Hubackova L, Vanek J, et al. Cognitive function and depressivity before and after cpap treatment in obstructive sleep apnea patients. Neuro endocrinology letters. 2017;38(3):145-153.
  194. Yan B, Jin Y, Hu Y, Li S. Effects of continuous positive airway pressure on elderly patients with obstructive sleep apnea: a meta-analysis. Medecine sciences : M/S. 2018;34 Focus issue F1:66-73.
  195. Devita M, Zangrossi A, Marvisi M, Merlo P, Rusconi ML, Mondini S. Global cognitive profile and different components of reaction times in obstructive sleep apnea syndrome: Effects of continuous positive airway pressure over time. International journal of psychophysiology : official journal of the International Organization of Psychophysiology. 2018;123:121-126.
  196. Eleftheriou D, Benetou V, Trichopoulou A, La Vecchia C, Bamia C. Mediterranean diet and its components in relation to all-cause mortality: meta-analysis. The British journal of nutrition. 2018;120(10):1081-1097.
  197. Carlos S, De La Fuente-Arrillaga C, Bes-Rastrollo M, et al. Mediterranean Diet and Health Outcomes in the SUN Cohort. Nutrients. 2018;10(4).
  198. Romagnolo DF, Selmin OI. Mediterranean Diet and Prevention of Chronic Diseases. Nutrition today. 2017;52(5):208-222.
  199. Aridi YS, Walker JL, Wright ORL. The Association between the Mediterranean Dietary Pattern and Cognitive Health: A Systematic Review. Nutrients. 2017;9(7).
  200. Martinez-Gonzalez MA, Hershey MS, Zazpe I, Trichopoulou A. Transferability of the Mediterranean Diet to Non-Mediterranean Countries. What Is and What Is Not the Mediterranean Diet. Nutrients. 2017;9(11).
  201. Tanaka T, Talegawkar SA, Jin Y, Colpo M, Ferrucci L, Bandinelli S. Adherence to a Mediterranean Diet Protects from Cognitive Decline in the Invecchiare in Chianti Study of Aging. Nutrients. 2018;10(12).
  202. Bhushan A, Fondell E, Ascherio A, Yuan C, Grodstein F, Willett W. Adherence to Mediterranean diet and subjective cognitive function in men. European journal of epidemiology. 2018;33(2):223-234.
  203. Vassilaki M, Aakre JA, Syrjanen JA, et al. Mediterranean Diet, Its Components, and Amyloid Imaging Biomarkers. J Alzheimers Dis. 2018;64(1):281-290.
  204. Rainey-Smith SR, Gu Y, Gardener SL, et al. Mediterranean diet adherence and rate of cerebral Abeta-amyloid accumulation: Data from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. Translational psychiatry. 2018;8(1):238.
  205. Qosa H, Mohamed LA, Batarseh YS, et al. Extra-virgin olive oil attenuates amyloid-beta and tau pathologies in the brains of TgSwDI mice. J Nutr Biochem. 2015;26(12):1479-1490.
  206. Batarseh YS, Mohamed LA, Al Rihani SB, et al. Oleocanthal ameliorates amyloid-beta oligomers' toxicity on astrocytes and neuronal cells: In vitro studies. Neuroscience. 2017;352:204-215.
  207. Luceri C, Bigagli E, Pitozzi V, Giovannelli L. A nutrigenomics approach for the study of anti-aging interventions: olive oil phenols and the modulation of gene and microRNA expression profiles in mouse brain. European journal of nutrition. 2017;56(2):865-877.
  208. Martinez-Lapiscina EH, Clavero P, Toledo E, et al. Virgin olive oil supplementation and long-term cognition: the PREDIMED-NAVARRA randomized, trial. The journal of nutrition, health & aging. 2013;17(6):544-552.
  209. Carman AJ, Dacks PA, Lane RF, Shineman DW, Fillit HM. Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer's disease. The journal of nutrition, health & aging. 2014;18(4):383-392.
  210. Haller S, Montandon ML, Rodriguez C, Herrmann FR, Giannakopoulos P. Impact of Coffee, Wine, and Chocolate Consumption on Cognitive Outcome and MRI Parameters in Old Age. Nutrients. 2018;10(10).
  211. Liu QP, Wu YF, Cheng HY, et al. Habitual coffee consumption and risk of cognitive decline/dementia: A systematic review and meta-analysis of prospective cohort studies. Nutrition (Burbank, Los Angeles County, Calif). 2016;32(6):628-636.
  212. Wu L, Sun D, He Y. Coffee intake and the incident risk of cognitive disorders: A dose-response meta-analysis of nine prospective cohort studies. Clin Nutr. 2017;36(3):730-736.
  213. Solfrizzi V, Panza F, Imbimbo BP, et al. Coffee Consumption Habits and the Risk of Mild Cognitive Impairment: The Italian Longitudinal Study on Aging. J Alzheimers Dis. 2015;47(4):889-899.
  214. Araujo LF, Giatti L, Reis RC, et al. Inconsistency of Association between Coffee Consumption and Cognitive Function in Adults and Elderly in a Cross-Sectional Study (ELSA-Brasil). Nutrients. 2015;7(11):9590-9601.
  215. Araujo LF, Mirza SS, Bos D, et al. Association of Coffee Consumption with MRI Markers and Cognitive Function: A Population-Based Study. J Alzheimers Dis. 2016;53(2):451-461.
  216. Most J, Tosti V, Redman LM, Fontana L. Calorie restriction in humans: An update. Ageing research reviews. 2017;39:36-45.
  217. Mattson MP. The impact of dietary energy intake on cognitive aging. Frontiers in aging neuroscience. 2010;2:5.
  218. Fusco S, Pani G. Brain response to calorie restriction. Cellular and molecular life sciences : CMLS. 2013;70(17):3157-3170.
  219. Park JH, Glass Z, Sayed K, et al. Calorie restriction alleviates the age-related decrease in neural progenitor cell division in the aging brain. Eur J Neurosci. 2013;37(12):1987-1993.
  220. Babenko NA, Shakhova EG. Long-term food restriction prevents aging-associated sphingolipid turnover dysregulation in the brain. Arch Gerontol Geriatr. 2014;58(3):420-426.
  221. Willette AA, Coe CL, Colman RJ, et al. Calorie restriction reduces psychological stress reactivity and its association with brain volume and microstructure in aged rhesus monkeys. Psychoneuroendocrinology. 2012;37(7):903-916.
  222. Hadad N, Unnikrishnan A, Jackson JA, et al. Caloric restriction mitigates age-associated hippocampal differential CG and non-CG methylation. Neurobiol Aging. 2018;67:53-66.
  223. Campagna G, Pesce M, Tatangelo R, Rizzuto A, La Fratta I, Grilli A. The progression of coeliac disease: its neurological and psychiatric implications. Nutr Res Rev. 2017;30(1):25-35.
  224. Casella G, Bordo BM, Schalling R, et al. Neurological disorders and celiac disease. Minerva gastroenterologica e dietologica. 2016;62(2):197-206.
  225. Makhlouf S, Messelmani M, Zaouali J, Mrissa R. Cognitive impairment in celiac disease and non-celiac gluten sensitivity: review of literature on the main cognitive impairments, the imaging and the effect of gluten free diet. Acta neurologica Belgica. 2018;118(1):21-27.
  226. Daulatzai MA. Non-celiac gluten sensitivity triggers gut dysbiosis, neuroinflammation, gut-brain axis dysfunction, and vulnerability for dementia. CNS & neurological disorders drug targets. 2015;14(1):110-131.
  227. Lurie Y, Landau DA, Pfeffer J, Oren R. Celiac disease diagnosed in the elderly. Journal of clinical gastroenterology. 2008;42(1):59-61.
  228. Zhang HF, Huang LB, Zhong YB, et al. An Overview of Systematic Reviews of Ginkgo biloba Extracts for Mild Cognitive Impairment and Dementia. Frontiers in aging neuroscience. 2016;8:276.
  229. Gargouri B, Carstensen J, Bhatia HS, Huell M, Dietz GPH, Fiebich BL. Anti-neuroinflammatory effects of Ginkgo biloba extract EGb761 in LPS-activated primary microglial cells. Phytomedicine. 2018;44:45-55.
  230. Osman NM, Amer AS, Abdelwahab S. Effects of Ginko biloba leaf extract on the neurogenesis of the hippocampal dentate gyrus in the elderly mice. Anatomical science international. 2016;91(3):280-289.
  231. Tan MS, Yu JT, Tan CC, et al. Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis. J Alzheimers Dis. 2015;43(2):589-603.
  232. Hashiguchi M, Ohta Y, Shimizu M, Maruyama J, Mochizuki M. Meta-analysis of the efficacy and safety of Ginkgo biloba extract for the treatment of dementia. Journal of pharmaceutical health care and sciences. 2015;1:14.
  233. Gauthier S, Schlaefke S. Efficacy and tolerability of Ginkgo biloba extract EGb 761(R) in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials. Clin Interv Aging. 2014;9:2065-2077.
  234. Kandiah N, Ong PA, Yuda T, et al. Treatment of dementia and mild cognitive impairment with or without cerebrovascular disease: Expert consensus on the use of Ginkgo biloba extract, EGb 761((R)). CNS neuroscience & therapeutics. 2019;25(2):288-298.
  235. Stough C, Singh H, Zangara A. Mechanisms, Efficacy, and Safety of Bacopa monnieri (Brahmi) for Cognitive and Brain Enhancement. Evidence-based complementary and alternative medicine : eCAM. 2015;2015:717605.
  236. Chaudhari KS, Tiwari NR, Tiwari RR, Sharma RS. Neurocognitive Effect of Nootropic Drug Brahmi (Bacopa monnieri) in Alzheimer's Disease. Annals of neurosciences. 2017;24(2):111-122.
  237. Aguiar S, Borowski T. Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Res. 2013;16(4):313-326.
  238. Benson S, Downey LA, Stough C, Wetherell M, Zangara A, Scholey A. An acute, double-blind, placebo-controlled cross-over study of 320 mg and 640 mg doses of Bacopa monnieri (CDRI 08) on multitasking stress reactivity and mood. Phytotherapy research : PTR. 2014;28(4):551-559.
  239. Kwon HJ, Jung HY, Hahn KR, et al. Bacopa monnieri extract improves novel object recognition, cell proliferation, neuroblast differentiation, brain-derived neurotrophic factor, and phosphorylation of cAMP response element-binding protein in the dentate gyrus. Laboratory animal research. 2018;34(4):239-247.
  240. Kongkeaw C, Dilokthornsakul P, Thanarangsarit P, Limpeanchob N, Norman Scholfield C. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. Journal of ethnopharmacology. 2014;151(1):528-535.
  241. Calabrese C, Gregory WL, Leo M, Kraemer D, Bone K, Oken B. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. Journal of alternative and complementary medicine (New York, NY). 2008;14(6):707-713.
  242. Zanotta D, Puricelli S, Bonoldi G. Cognitive effects of a dietary supplement made from extract of Bacopa monnieri, astaxanthin, phosphatidylserine, and vitamin E in subjects with mild cognitive impairment: a noncomparative, exploratory clinical study. Neuropsychiatric disease and treatment. 2014;10:225-230.
  243. Cicero AF, Bove M, Colletti A, et al. Short-Term Impact of a Combined Nutraceutical on Cognitive Function, Perceived Stress and Depression in Young Elderly with Cognitive Impairment: A Pilot, Double-Blind, Randomized Clinical Trial. The journal of prevention of Alzheimer's disease. 2017;4(1):12-15.
  244. Janeczek M, Gefen T, Samimi M, et al. Variations in Acetylcholinesterase Activity within Human Cortical Pyramidal Neurons Across Age and Cognitive Trajectories. Cerebral cortex (New York, NY : 1991). 2018;28(4):1329-1337.
  245. Damar U, Gersner R, Johnstone JT, Schachter S, Rotenberg A. Huperzine A: A promising anticonvulsant, disease modifying, and memory enhancing treatment option in Alzheimer's disease. Med Hypotheses. 2017;99:57-62.
  246. Qian ZM, Ke Y. Huperzine A: Is it an Effective Disease-Modifying Drug for Alzheimer's Disease? Frontiers in aging neuroscience. 2014;6:216.
  247. Xing SH, Zhu CX, Zhang R, An L. Huperzine a in the treatment of Alzheimer's disease and vascular dementia: a meta-analysis. Evidence-based complementary and alternative medicine : eCAM. 2014;2014:363985.
  248. Yang G, Wang Y, Tian J, Liu JP. Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. PLoS One. 2013;8(9):e74916.
  249. Gul A, Bakht J, Mehmood F. Huperzine-A response to cognitive impairment and task switching deficits in patients with Alzheimer's disease. Journal of the Chinese Medical Association : JCMA. 2018.
  250. Tabira T, Kawamura N. A Study of a Supplement Containing Huperzine A and Curcumin in Dementia Patients and Individuals with Mild Cognitive Impairment. J Alzheimers Dis. 2018;63(1):75-78.
  251. Cristofano A, Sapere N, La Marca G, et al. Serum Levels of Acyl-Carnitines along the Continuum from Normal to Alzheimer's Dementia. PLoS One. 2016;11(5):e0155694.
  252. Mehrotra A, Kanwal A, Banerjee SK, Sandhir R. Mitochondrial modulators in experimental Huntington's disease: reversal of mitochondrial dysfunctions and cognitive deficits. Neurobiol Aging. 2015;36(6):2186-2200.
  253. Singh S, Mishra A, Srivastava N, Shukla R, Shukla S. Acetyl-L-Carnitine via Upegulating Dopamine D1 Receptor and Attenuating Microglial Activation Prevents Neuronal Loss and Improves Memory Functions in Parkinsonian Rats. Molecular neurobiology. 2018;55(1):583-602.
  254. Montgomery SA, Thal LJ, Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. International clinical psychopharmacology. 2003;18(2):61-71.
  255. Malaguarnera M, Gargante MP, Cristaldi E, et al. Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue. Archives of gerontology and geriatrics. 2008;46(2):181-190.
  256. Bersani G, Meco G, Denaro A, et al. L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2013;23(10):1219-1225.
  257. Remington R, Lortie JJ, Hoffmann H, Page R, Morrell C, Shea TB. A Nutritional Formulation for Cognitive Performance in Mild Cognitive Impairment: A Placebo-Controlled Trial with an Open-Label Extension. J Alzheimers Dis. 2015;48(3):591-595.
  258. Slutsky I, Abumaria N, Wu LJ, et al. Enhancement of learning and memory by elevating brain magnesium. Neuron. 2010;65(2):165-177.
  259. Wang D, Jacobs SA, Tsien JZ. Targeting the NMDA receptor subunit NR2B for treating or preventing age-related memory decline. Expert opinion on therapeutic targets. 2014;18(10):1121-1130.
  260. Abumaria N, Yin B, Zhang L, et al. Effects of elevation of brain magnesium on fear conditioning, fear extinction, and synaptic plasticity in the infralimbic prefrontal cortex and lateral amygdala. J Neurosci. 2011;31(42):14871-14881.
  261. Yu X, Guan PP, Zhu D, et al. Magnesium Ions Inhibit the Expression of Tumor Necrosis Factor alpha and the Activity of gamma-Secretase in a beta-Amyloid Protein-Dependent Mechanism in APP/PS1 Transgenic Mice. Frontiers in molecular neuroscience. 2018;11:172.
  262. Yu X, Guan PP, Guo JW, et al. By suppressing the expression of anterior pharynx-defective-1alpha and -1beta and inhibiting the aggregation of beta-amyloid protein, magnesium ions inhibit the cognitive decline of amyloid precursor protein/presenilin 1 transgenic mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2015;29(12):5044-5058.
  263. Li W, Yu J, Liu Y, et al. Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer's disease mouse model. Molecular brain. 2014;7:65.
  264. Huang Y, Huang X, Zhang L, et al. Magnesium boosts the memory restorative effect of environmental enrichment in Alzheimer's disease mice. CNS neuroscience & therapeutics. 2018;24(1):70-79.
  265. Valls-Pedret C, Lamuela-Raventos RM, Medina-Remon A, et al. Polyphenol-rich foods in the Mediterranean diet are associated with better cognitive function in elderly subjects at high cardiovascular risk. J Alzheimers Dis. 2012;29(4):773-782.
  266. Rabassa M, Cherubini A, Zamora-Ros R, et al. Low Levels of a Urinary Biomarker of Dietary Polyphenol Are Associated with Substantial Cognitive Decline over a 3-Year Period in Older Adults: The Invecchiare in Chianti Study. J Am Geriatr Soc. 2015;63(5):938-946.
  267. Flanagan E, Muller M, Hornberger M, Vauzour D. Impact of Flavonoids on Cellular and Molecular Mechanisms Underlying Age-Related Cognitive Decline and Neurodegeneration. Current nutrition reports. 2018;7(2):49-57.
  268. Sarubbo F, Moranta D, Pani G. Dietary polyphenols and neurogenesis: Molecular interactions and implication for brain ageing and cognition. Neuroscience and biobehavioral reviews. 2018;90:456-470.
  269. Caracciolo B, Xu W, Collins S, Fratiglioni L. Cognitive decline, dietary factors and gut-brain interactions. Mech Ageing Dev. 2014;136-137:59-69.
  270. Frolinger T, Herman F, Sharma A, Sims S, Wang J, Pasinetti GM. Epigenetic modifications by polyphenolic compounds alter gene expression in the hippocampus. Biology open. 2018;7(10).
  271. Ma L, Sun Z, Zeng Y, Luo M, Yang J. Molecular Mechanism and Health Role of Functional Ingredients in Blueberry for Chronic Disease in Human Beings. International journal of molecular sciences. 2018;19(9).
  272. Boespflug EL, Eliassen JC, Dudley JA, et al. Enhanced neural activation with blueberry supplementation in mild cognitive impairment. Nutritional neuroscience. 2018;21(4):297-305.
  273. Bowtell JL, Aboo-Bakkar Z, Conway ME, Adlam AR, Fulford J. Enhanced task-related brain activation and resting perfusion in healthy older adults after chronic blueberry supplementation. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme. 2017;42(7):773-779.
  274. Miller MG, Hamilton DA, Joseph JA, Shukitt-Hale B. Dietary blueberry improves cognition among older adults in a randomized, double-blind, placebo-controlled trial. European journal of nutrition. 2018;57(3):1169-1180.
  275. McNamara RK, Kalt W, Shidler MD, et al. Cognitive response to fish oil, blueberry, and combined supplementation in older adults with subjective cognitive impairment. Neurobiol Aging. 2018;64:147-156.
  276. Traupe I, Giacalone M, Agrimi J, et al. Postoperative cognitive dysfunction and short-term neuroprotection from blueberries: a pilot study. Minerva Anestesiol. 2018;84(12):1352-1360.
  277. Nilsson A, Salo I, Plaza M, Bjorck I. Effects of a mixed berry beverage on cognitive functions and cardiometabolic risk markers; A randomized cross-over study in healthy older adults. PloS one. 2017;12(11):e0188173.
  278. Herman F, Westfall S, Brathwaite J, Pasinetti GM. Suppression of Presymptomatic Oxidative Stress and Inflammation in Neurodegeneration by Grape-Derived Polyphenols. Frontiers in pharmacology. 2018;9:867.
  279. Calapai G, Bonina F, Bonina A, et al. A Randomized, Double-Blinded, Clinical Trial on Effects of a Vitis vinifera Extract on Cognitive Function in Healthy Older Adults. Frontiers in pharmacology. 2017;8:776.
  280. Krikorian R, Boespflug EL, Fleck DE, et al. Concord grape juice supplementation and neurocognitive function in human aging. J Agric Food Chem. 2012;60(23):5736-5742.
  281. Krikorian R, Nash TA, Shidler MD, Shukitt-Hale B, Joseph JA. Concord grape juice supplementation improves memory function in older adults with mild cognitive impairment. The British journal of nutrition. 2010;103(5):730-734.
  282. Lee J, Torosyan N, Silverman DH. Examining the impact of grape consumption on brain metabolism and cognitive function in patients with mild decline in cognition: A double-blinded placebo controlled pilot study. Exp Gerontol. 2017;87(Pt A):121-128.
  283. Bensalem J, Dudonne S, Etchamendy N, et al. Polyphenols from grape and blueberry improve episodic memory in healthy elderly with lower level of memory performance: a bicentric double-blind, randomized, placebo-controlled clinical study. The journals of gerontology Series A, Biological sciences and medical sciences. 2018.
  284. Ramirez-Garza SL, Laveriano-Santos EP, Marhuenda-Munoz M, et al. Health Effects of Resveratrol: Results from Human Intervention Trials. Nutrients. 2018;10(12).
  285. Cao W, Dou Y, Li A. Resveratrol Boosts Cognitive Function by Targeting SIRT1. Neurochem Res. 2018;43(9):1705-1713.
  286. Marx W, Kelly JT, Marshall S, et al. Effect of resveratrol supplementation on cognitive performance and mood in adults: a systematic literature review and meta-analysis of randomized controlled trials. Nutrition reviews. 2018;76(6):432-443.
  287. Witte AV, Kerti L, Margulies DS, Floel A. Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. J Neurosci. 2014;34(23):7862-7870.
  288. Kobe T, Witte AV, Schnelle A, et al. Impact of Resveratrol on Glucose Control, Hippocampal Structure and Connectivity, and Memory Performance in Patients with Mild Cognitive Impairment. Front Neurosci. 2017;11:105.
  289. Anton SD, Ebner N, Dzierzewski JM, et al. Effects of 90 Days of Resveratrol Supplementation on Cognitive Function in Elders: A Pilot Study. Journal of alternative and complementary medicine (New York, NY). 2018;24(7):725-732.
  290. Evans HM, Howe PR, Wong RH. Effects of Resveratrol on Cognitive Performance, Mood and Cerebrovascular Function in Post-Menopausal Women; A 14-Week Randomised Placebo-Controlled Intervention Trial. Nutrients. 2017;9(1).
  291. Farzaei MH, Bahramsoltani R, Abbasabadi Z, Braidy N, Nabavi SM. Role of green tea catechins in prevention of age-related cognitive decline: Pharmacological targets and clinical perspective. Journal of cellular physiology. 2019;234(3):2447-2459.
  292. Pervin M, Unno K, Ohishi T, Tanabe H, Miyoshi N, Nakamura Y. Beneficial Effects of Green Tea Catechins on Neurodegenerative Diseases. Molecules (Basel, Switzerland). 2018;23(6).
  293. Mancini E, Beglinger C, Drewe J, Zanchi D, Lang UE, Borgwardt S. Green tea effects on cognition, mood and human brain function: A systematic review. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2017;34:26-37.
  294. Heitman E, Ingram DK. Cognitive and neuroprotective effects of chlorogenic acid. Nutritional neuroscience. 2017;20(1):32-39.
  295. Saitou K, Ochiai R, Kozuma K, et al. Effect of Chlorogenic Acids on Cognitive Function: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients. 2018;10(10).
  296. Spinedi E, Cardinali DP. Neuroendocrine-Metabolic Dysfunction and Sleep Disturbances in Neurodegenerative Disorders: Focus on Alzheimer s Disease and Melatonin. <br>. Neuroendocrinology. 2018.
  297. Sarlak G, Jenwitheesuk A, Chetsawang B, Govitrapong P. Effects of melatonin on nervous system aging: neurogenesis and neurodegeneration. Journal of pharmacological sciences. 2013;123(1):9-24.
  298. Waller KL, Mortensen EL, Avlund K, et al. Melatonin and cortisol profiles in late midlife and their association with age-related changes in cognition. Nature and science of sleep. 2016;8:47-53.
  299. Sirin FB, Kumbul Doguc D, Vural H, et al. Plasma 8-isoPGF2alpha and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease. Turkish journal of medical sciences. 2015;45(5):1073-1077.
  300. Obayashi K, Saeki K, Iwamoto J, et al. Physiological Levels of Melatonin Relate to Cognitive Function and Depressive Symptoms: The HEIJO-KYO Cohort. J Clin Endocrinol Metab. 2015;100(8):3090-3096.
  301. Xia T, Cui Y, Chu S, et al. Melatonin pretreatment prevents isoflurane-induced cognitive dysfunction by modulating sleep-wake rhythm in mice. Brain research. 2016;1634:12-20.
  302. Kwon KJ, Lee EJ, Kim MK, et al. The potential role of melatonin on sleep deprivation-induced cognitive impairments: implication of FMRP on cognitive function. Neuroscience. 2015;301:403-414.
  303. Song J, Chu S, Cui Y, et al. Circadian rhythm resynchronization improved isoflurane-induced cognitive dysfunction in aged mice. Experimental neurology. 2018;306:45-54.
  304. Shen D, Tian X, Sang W, Song R. Effect of Melatonin and Resveratrol against Memory Impairment and Hippocampal Damage in a Rat Model of Vascular Dementia. Neuroimmunomodulation. 2016;23(5-6):318-331.
  305. Corpas R, Grinan-Ferre C, Palomera-Avalos V, et al. Melatonin induces mechanisms of brain resilience against neurodegeneration. Journal of pineal research. 2018;65(4):e12515.
  306. Permpoonputtana K, Tangweerasing P, Mukda S, Boontem P, Nopparat C, Govitrapong P. Long-term administration of melatonin attenuates neuroinflammation in the aged mouse brain. EXCLI journal. 2018;17:634-646.
  307. Cardinali DP, Vigo DE, Olivar N, Vidal MF, Furio AM, Brusco LI. Therapeutic application of melatonin in mild cognitive impairment. American journal of neurodegenerative disease. 2012;1(3):280-291.
  308. Furio AM, Brusco LI, Cardinali DP. Possible therapeutic value of melatonin in mild cognitive impairment: a retrospective study. Journal of pineal research. 2007;43(4):404-409.
  309. Jean-Louis G, von Gizycki H, Zizi F. Melatonin effects on sleep, mood, and cognition in elderly with mild cognitive impairment. Journal of pineal research. 1998;25(3):177-183.
  310. Fan Y, Yuan L, Ji M, Yang J, Gao D. The effect of melatonin on early postoperative cognitive decline in elderly patients undergoing hip arthroplasty: A randomized controlled trial. Journal of clinical anesthesia. 2017;39:77-81.
  311. Srinivasan V, Pandi-Perumal SR, Cardinali DP, Poeggeler B, Hardeland R. Melatonin in Alzheimer's disease and other neurodegenerative disorders. Behavioral and brain functions : BBF. 2006;2:15.
  312. Cardinali DP, Vigo DE, Olivar N, Vidal MF, Brusco LI. Melatonin Therapy in Patients with Alzheimer's Disease. Antioxidants (Basel, Switzerland). 2014;3(2):245-277.
  313. Cardoso C, Afonso C, Bandarra NM. Dietary DHA and health: cognitive function ageing. Nutrition research reviews. 2016;29(2):281-294.
  314. Rathod R, Kale A, Joshi S. Novel insights into the effect of vitamin B(1)(2) and omega-3 fatty acids on brain function. J Biomed Sci. 2016;23:17.
  315. Morris MC, Brockman J, Schneider JA, et al. Association of Seafood Consumption, Brain Mercury Level, and APOE epsilon4 Status With Brain Neuropathology in Older Adults. Jama. 2016;315(5):489-497.
  316. Luo C, Ren H, Yao X, et al. Enriched Brain Omega-3 Polyunsaturated Fatty Acids Confer Neuroprotection against Microinfarction. EBioMedicine. 2018;32:50-61.
  317. Oulhaj A, Jerneren F, Refsum H, Smith AD, de Jager CA. Omega-3 Fatty Acid Status Enhances the Prevention of Cognitive Decline by B Vitamins in Mild Cognitive Impairment. J Alzheimers Dis. 2016;50(2):547-557.
  318. Nishihira J, Tokashiki T, Higashiuesato Y, et al. Associations between Serum Omega-3 Fatty Acid Levels and Cognitive Functions among Community-Dwelling Octogenarians in Okinawa, Japan: The KOCOA Study. J Alzheimers Dis. 2016;51(3):857-866.
  319. Lukaschek K, von Schacky C, Kruse J, Ladwig KH. Cognitive Impairment Is Associated with a Low Omega-3 Index in the Elderly: Results from the KORA-Age Study. Dement Geriatr Cogn Disord. 2016;42(3-4):236-245.
  320. D'Ascoli TA, Mursu J, Voutilainen S, Kauhanen J, Tuomainen TP, Virtanen JK. Association between serum long-chain omega-3 polyunsaturated fatty acids and cognitive performance in elderly men and women: The Kuopio Ischaemic Heart Disease Risk Factor Study. European journal of clinical nutrition. 2016;70(8):970-975.
  321. Lai HT, de Oliveira Otto MC, Lemaitre RN, et al. Serial circulating omega 3 polyunsaturated fatty acids and healthy ageing among older adults in the Cardiovascular Health Study: prospective cohort study. BMJ (Clinical research ed). 2018;363:k4067.
  322. Zamroziewicz MK, Paul EJ, Zwilling CE, Barbey AK. Predictors of Memory in Healthy Aging: Polyunsaturated Fatty Acid Balance and Fornix White Matter Integrity. Aging Dis. 2017;8(4):372-383.
  323. Andruchow ND, Konishi K, Shatenstein B, Bohbot VD. A lower ratio of omega-6 to omega-3 fatty acids predicts better hippocampus-dependent spatial memory and cognitive status in older adults. Neuropsychology. 2017;31(7):724-734.
  324. Zhang XW, Hou WS, Li M, Tang ZY. Omega-3 fatty acids and risk of cognitive decline in the elderly: a meta-analysis of randomized controlled trials. Aging clinical and experimental research. 2016;28(1):165-166.
  325. Masana MF, Koyanagi A, Haro JM, Tyrovolas S. n-3 Fatty acids, Mediterranean diet and cognitive function in normal aging: A systematic review. Exp Gerontol. 2017;91:39-50.
  326. Danthiir V, Hosking DE, Nettelbeck T, et al. An 18-mo randomized, double-blind, placebo-controlled trial of DHA-rich fish oil to prevent age-related cognitive decline in cognitively normal older adults. Am J Clin Nutr. 2018;107(5):754-762.
  327. Baleztena J, Ruiz-Canela M, Sayon-Orea C, et al. Association between cognitive function and supplementation with omega-3 PUFAs and other nutrients in >/= 75 years old patients: A randomized multicenter study. PLoS One. 2018;13(3):e0193568.
  328. Andrieu S, Guyonnet S, Coley N, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017;16(5):377-389.
  329. Hooper C, De Souto Barreto P, Coley N, et al. Cognitive Changes with Omega-3 Polyunsaturated Fatty Acids in Non-Demented Older Adults with Low Omega-3 Index. The journal of nutrition, health & aging. 2017;21(9):988-993.
  330. Coley N, Raman R, Donohue MC, Aisen PS, Vellas B, Andrieu S. Defining the Optimal Target Population for Trials of Polyunsaturated Fatty Acid Supplementation Using the Erythrocyte Omega-3 Index: A Step Towards Personalized Prevention of Cognitive Decline? The journal of nutrition, health & aging. 2018;22(8):982-998.
  331. Yassine HN, Croteau E, Rawat V, et al. DHA brain uptake and APOE4 status: a PET study with [1-(11)C]-DHA. Alzheimers Res Ther. 2017;9(1):23.
  332. van de Rest O, Wang Y, Barnes LL, Tangney C, Bennett DA, Morris MC. APOE epsilon4 and the associations of seafood and long-chain omega-3 fatty acids with cognitive decline. Neurology. 2016;86(22):2063-2070.
  333. Nock TG, Chouinard-Watkins R, Plourde M. Carriers of an apolipoprotein E epsilon 4 allele are more vulnerable to a dietary deficiency in omega-3 fatty acids and cognitive decline. Biochimica et biophysica acta Molecular and cell biology of lipids. 2017;1862(10 Pt A):1068-1078.
  334. Porter K, Hoey L, Hughes CF, Ward M, McNulty H. Causes, Consequences and Public Health Implications of Low B-Vitamin Status in Ageing. Nutrients. 2016;8(11).
  335. Mendonca N, Granic A, Mathers JC, et al. One-Carbon Metabolism Biomarkers and Cognitive Decline in the Very Old: The Newcastle 85+ Study. Journal of the American Medical Directors Association. 2017;18(9):806.e819-806.e827.
  336. Mizrahi EH, Lubart E, Leibovitz A. Low Borderline Levels of Serum Vitamin B12 May Predict Cognitive Decline in Elderly Hip Fracture Patients. The Israel Medical Association journal : IMAJ. 2017;19(5):305-308.
  337. Hughes CF, Ward M, Tracey F, et al. B-Vitamin Intake and Biomarker Status in Relation to Cognitive Decline in Healthy Older Adults in a 4-Year Follow-Up Study. Nutrients. 2017;9(1).
  338. Zhang DM, Ye JX, Mu JS, Cui XP. Efficacy of Vitamin B Supplementation on Cognition in Elderly Patients With Cognitive-Related Diseases. Journal of geriatric psychiatry and neurology. 2017;30(1):50-59.
  339. Rutjes AW, Denton DA, Di Nisio M, et al. Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life. The Cochrane database of systematic reviews. 2018;12:Cd011906.
  340. D'Cunha NM, Georgousopoulou EN, Dadigamuwage L, et al. Effect of long-term nutraceutical and dietary supplement use on cognition in the elderly: a 10-year systematic review of randomised controlled trials. The British journal of nutrition. 2018;119(3):280-298.
  341. Butler M, Nelson VA, Davila H, et al. Over-the-Counter Supplement Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review. Ann Intern Med. 2018;168(1):52-62.
  342. de Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. International journal of geriatric psychiatry. 2012;27(6):592-600.
  343. Blasko I, Hinterberger M, Kemmler G, et al. Conversion from mild cognitive impairment to dementia: influence of folic acid and vitamin B12 use in the VITA cohort. The journal of nutrition, health & aging. 2012;16(8):687-694.
  344. Ma F, Wu T, Zhao J, et al. Effects of 6-Month Folic Acid Supplementation on Cognitive Function and Blood Biomarkers in Mild Cognitive Impairment: A Randomized Controlled Trial in China. The journals of gerontology Series A, Biological sciences and medical sciences. 2016;71(10):1376-1383.
  345. Ma F, Wu T, Zhao J, et al. Folic acid supplementation improves cognitive function by reducing the levels of peripheral inflammatory cytokines in elderly Chinese subjects with MCI. Sci Rep. 2016;6:37486.
  346. Lee HK, Kim SY, Sok SR. Effects of Multivitamin Supplements on Cognitive Function, Serum Homocysteine Level, and Depression of Korean Older Adults With Mild Cognitive Impairment in Care Facilities. Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing. 2016;48(3):223-231.
  347. Mitchell ES, Conus N, Kaput J. B vitamin polymorphisms and behavior: evidence of associations with neurodevelopment, depression, schizophrenia, bipolar disorder and cognitive decline. Neuroscience and biobehavioral reviews. 2014;47:307-320.
  348. Hara J, Shankle WR, Barrentine LW, Curole MV. Novel Therapy of Hyperhomocysteinemia in Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementing Disorders. The journal of nutrition, health & aging. 2016;20(8):825-834.
  349. Scapicchio PL. Revisiting choline alphoscerate profile: a new, perspective, role in dementia? Int J Neurosci. 2013;123(7):444-449.
  350. Traini E, Bramanti V, Amenta F. Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline- containing phospholipid with a still interesting profile as cognition enhancing agent. Current Alzheimer research. 2013;10(10):1070-1079.
  351. Tayebati SK, Amenta F. Choline-containing phospholipids: relevance to brain functional pathways. Clinical chemistry and laboratory medicine : CCLM / FESCC. 2013;51(3):513-521.
  352. De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clinical therapeutics. 2003;25(1):178-193.
  353. Gavrilova SI, Kolykhalov IV, Ponomareva EV, Fedorova YB, Selezneva ND. [Clinical efficacy and safety of choline alfoscerate in the treatment of late-onset cognitive impairment]. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(5):45-53.
  354. Pizova NV. [The use of cereton in patients with chronic brain ischemia and moderate cognitive impairment]. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(12):78-83.
  355. Amenta F, Carotenuto A, Fasanaro AM, Rea R, Traini E. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results. J Neurol Sci. 2012;322(1-2):96-101.
  356. Amenta F, Carotenuto A, Fasanaro AM, Rea R, Traini E. The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer's Disease) Trial: interim results after two years of treatment. J Alzheimers Dis. 2014;42 Suppl 3:S281-288.
  357. Rea R, Carotenuto A, Traini E, Fasanaro AM, Manzo V, Amenta F. Apathy Treatment in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial. J Alzheimers Dis. 2015;48(2):377-383.
  358. Carotenuto A, Rea R, Traini E, et al. The Effect of the Association between Donepezil and Choline Alphoscerate on Behavioral Disturbances in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial. J Alzheimers Dis. 2017;56(2):805-815.
  359. Glade MJ, Smith K. Phosphatidylserine and the human brain. Nutrition (Burbank, Los Angeles County, Calif). 2015;31(6):781-786.
  360. Vakhapova V, Cohen T, Richter Y, Herzog Y, Kam Y, Korczyn AD. Phosphatidylserine containing omega-3 Fatty acids may improve memory abilities in nondemented elderly individuals with memory complaints: results from an open-label extension study. Dementia and geriatric cognitive disorders. 2014;38(1-2):39-45.
  361. Maggioni M, Picotti GB, Bondiolotti GP, et al. Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. Acta psychiatrica Scandinavica. 1990;81(3):265-270.
  362. Cenacchi T, Bertoldin T, Farina C, Fiori MG, Crepaldi G. Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging (Milan, Italy). 1993;5(2):123-133.
  363. Kato-Kataoka A, Sakai M, Ebina R, Nonaka C, Asano T, Miyamori T. Soybean-derived phosphatidylserine improves memory function of the elderly Japanese subjects with memory complaints. Journal of clinical biochemistry and nutrition. 2010;47(3):246-255.
  364. Richter Y, Herzog Y, Lifshitz Y, Hayun R, Zchut S. The effect of soybean-derived phosphatidylserine on cognitive performance in elderly with subjective memory complaints: a pilot study. Clin Interv Aging. 2013;8:557-563.
  365. Vakhapova V, Richter Y, Cohen T, Herzog Y, Korczyn AD. Safety of phosphatidylserine containing omega-3 fatty acids in non-demented elderly: a double-blind placebo-controlled trial followed by an open-label extension. BMC Neurol. 2011;11:79.
  366. Richter Y, Herzog Y, Cohen T, Steinhart Y. The effect of phosphatidylserine-containing omega-3 fatty acids on memory abilities in subjects with subjective memory complaints: a pilot study. Clinical interventions in aging. 2010;5:313-316.
  367. Vakhapova V, Cohen T, Richter Y, Herzog Y, Korczyn AD. Phosphatidylserine containing omega-3 fatty acids may improve memory abilities in non-demented elderly with memory complaints: a double-blind placebo-controlled trial. Dement Geriatr Cogn Disord. 2010;29(5):467-474.
  368. Rathe M, Muller K, Sangild PT, Husby S. Clinical applications of bovine colostrum therapy: a systematic review. Nutrition reviews. 2014;72(4):237-254.
  369. Bagwe S, Tharappel LJ, Kaur G, Buttar HS. Bovine colostrum: an emerging nutraceutical. Journal of complementary & integrative medicine. 2015;12(3):175-185.
  370. Camfield DA, Owen L, Scholey AB, Pipingas A, Stough C. Dairy constituents and neurocognitive health in ageing. The British journal of nutrition. 2011;106(2):159-174.
  371. Janusz M, Zablocka A. Colostrinin: a proline-rich polypeptide complex of potential therapeutic interest. Cellular and molecular biology (Noisy-le-Grand, France). 2013;59(1):4-11.
  372. Bacsi A, Aguilera-Aguirre L, German P, Kruzel ML, Boldogh I. Colostrinin decreases spontaneous and induced mutation frequencies at the hprt locus in Chinese hamster V79 cells. Journal of experimental therapeutics & oncology. 2006;5(4):249-259.
  373. Bacsi A, Woodberry M, Kruzel ML, Boldogh I. Colostrinin delays the onset of proliferative senescence of diploid murine fibroblast cells. Neuropeptides. 2007;41(2):93-101.
  374. Zablocka A, Ogorzalek A, Macala J, Janusz M. A proline-rich polypeptide complex (PRP) influences inducible nitric oxide synthase in mice at the protein level. Nitric oxide : biology and chemistry. 2010;23(1):20-25.
  375. Zablocka A, Janusz M. Effect of the proline-rich polypeptide complex/colostrinin on the enzymatic antioxidant system. Arch Immunol Ther Exp (Warsz). 2012;60(5):383-390.
  376. Janusz M, Zablocka A. Colostral proline-rich polypeptides--immunoregulatory properties and prospects of therapeutic use in Alzheimer's disease. Current Alzheimer research. 2010;7(4):323-333.
  377. Bilikiewicz A, Gaus W. Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease. Journal of Alzheimer's disease : JAD. 2004;6(1):17-26.
  378. Leszek J, Inglot AD, Janusz M, et al. Colostrinin proline-rich polypeptide complex from ovine colostrum--a long-term study of its efficacy in Alzheimer's disease. Medical science monitor : international medical journal of experimental and clinical research. 2002;8(10):Pi93-96.
  379. Leszek J, Inglot AD, Janusz M, Lisowski J, Krukowska K, Georgiades JA. Colostrinin: a proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Archivum immunologiae et therapiae experimentalis. 1999;47(6):377-385.
  380. Jeon KI, Xu X, Aizawa T, et al. Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(21):9795-9800.
  381. Hadjiev D. Asymptomatic ischemic cerebrovascular disorders and neuroprotection with vinpocetine. Ideggyogyaszati szemle. 2003;56(5-6):166-172.
  382. Bagoly E, Feher G, Szapary L. [The role of vinpocetine in the treatment of cerebrovascular diseases based in human studies]. Orvosi hetilap. 2007;148(29):1353-1358.
  383. Cai Y, Li JD, Yan C. Vinpocetine attenuates lipid accumulation and atherosclerosis formation. Biochemical and biophysical research communications. 2013;434(3):439-443.
  384. Kemeny V, Molnar S, Andrejkovics M, Makai A, Csiba L. Acute and chronic effects of vinpocetine on cerebral hemodynamics and neuropsychological performance in multi-infarct patients. J Clin Pharmacol. 2005;45(9):1048-1054.
  385. Valikovics A, Csanyi A, Nemeth L. [Study of the effects of vinpocetin on cognitive functions]. Ideggyogyaszati szemle. 2012;65(3-4):115-120.
  386. Valikovics A. [Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions]. Ideggyogyaszati szemle. 2007;60(7-8):301-310.
  387. Rybakowski JK. Challenging the Negative Perception of Lithium and Optimizing Its Long-Term Administration. Frontiers in molecular neuroscience. 2018;11:349.
  388. Won E, Kim YK. An Oldie but Goodie: Lithium in the Treatment of Bipolar Disorder through Neuroprotective and Neurotrophic Mechanisms. International journal of molecular sciences. 2017;18(12).
  389. Kessing LV, Gerds TA, Knudsen NN, et al. Association of Lithium in Drinking Water With the Incidence of DementiaAssociation of Lithium in Drinking Water With Dementia IncidenceAssociation of Lithium in Drinking Water With Dementia Incidence. JAMA Psychiatry. 2017;74(10):1005-1010.
  390. Brown EE, Gerretsen P, Pollock B, Graff-Guerrero A. Psychiatric benefits of lithium in water supplies may be due to protection from the neurotoxicity of lead exposure. Med Hypotheses. 2018;115:94-102.
  391. Morris G, Berk M. The Putative Use of Lithium in Alzheimer's Disease. Current Alzheimer research. 2016;13(8):853-861.
  392. Brzozka MM, Havemann-Reinecke U, Wichert SP, Falkai P, Rossner MJ. Molecular Signatures of Psychosocial Stress and Cognition Are Modulated by Chronic Lithium Treatment. Schizophrenia bulletin. 2016;42 Suppl 1:S22-33.
  393. Kerr F, Bjedov I, Sofola-Adesakin O. Molecular Mechanisms of Lithium Action: Switching the Light on Multiple Targets for Dementia Using Animal Models. Frontiers in molecular neuroscience. 2018;11:297.
  394. De-Paula VJ, Gattaz WF, Forlenza OV. Long-term lithium treatment increases intracellular and extracellular brain-derived neurotrophic factor (BDNF) in cortical and hippocampal neurons at subtherapeutic concentrations. Bipolar disorders. 2016;18(8):692-695.
  395. Gideons ES, Lin PY, Mahgoub M, Kavalali ET, Monteggia LM. Chronic lithium treatment elicits its antimanic effects via BDNF-TrkB dependent synaptic downscaling. Elife. 2017;6.
  396. Valvassori SS, Borges CP, Varela RB, et al. The different effects of lithium and tamoxifen on memory formation and the levels of neurotrophic factors in the brain of male and female rats. Brain research bulletin. 2017;134:228-235.
  397. Matsunaga S, Kishi T, Annas P, Basun H, Hampel H, Iwata N. Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis. J Alzheimers Dis. 2015;48(2):403-410.
  398. Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. Current Alzheimer research. 2013;10(1):104-107.
  399. Wilson EN, Do Carmo S, Iulita MF, et al. Microdose Lithium NP03 Diminishes Pre-Plaque Oxidative Damage and Neuroinflammation in a Rat Model of Alzheimer's-like Amyloidosis. Current Alzheimer research. 2018;15(13):1220-1230.
  400. Wilson EN, Do Carmo S, Iulita MF, et al. BACE1 inhibition by microdose lithium formulation NP03 rescues memory loss and early stage amyloid neuropathology. Translational psychiatry. 2017;7(8):e1190.
  401. Rees A, Dodd GF, Spencer JPE. The Effects of Flavonoids on Cardiovascular Health: A Review of Human Intervention Trials and Implications for Cerebrovascular Function. Nutrients. 2018;10(12).
  402. Grassi D, Ferri C, Desideri G. Brain Protection and Cognitive Function: Cocoa Flavonoids as Nutraceuticals. Curr Pharm Des. 2016;22(2):145-151.
  403. Wang J, Varghese M, Ono K, et al. Cocoa extracts reduce oligomerization of amyloid-beta: implications for cognitive improvement in Alzheimer's disease. J Alzheimers Dis. 2014;41(2):643-650.
  404. Nehlig A. The neuroprotective effects of cocoa flavanol and its influence on cognitive performance. Br J Clin Pharmacol. 2013;75(3):716-727.
  405. Orozco Arbelaez E, Banegas JR, Rodriguez Artalejo F, Lopez Garcia E. [Influence of habitual chocolate consumption over the Mini-Mental State Examination in Spanish older adults]. Nutr Hosp. 2017;34(4):841-846.
  406. Moreira A, Diogenes MJ, de Mendonca A, Lunet N, Barros H. Chocolate Consumption is Associated with a Lower Risk of Cognitive Decline. J Alzheimers Dis. 2016;53(1):85-93.
  407. Neshatdoust S, Saunders C, Castle SM, et al. High-flavonoid intake induces cognitive improvements linked to changes in serum brain-derived neurotrophic factor: Two randomised, controlled trials. Nutr Healthy Aging. 2016;4(1):81-93.
  408. Mastroiacovo D, Kwik-Uribe C, Grassi D, et al. Cocoa flavanol consumption improves cognitive function, blood pressure control, and metabolic profile in elderly subjects: the Cocoa, Cognition, and Aging (CoCoA) Study--a randomized controlled trial. Am J Clin Nutr. 2015;101(3):538-548.
  409. Brickman AM, Khan UA, Provenzano FA, et al. Enhancing dentate gyrus function with dietary flavanols improves cognition in older adults. Nat Neurosci. 2014;17(12):1798-1803.
  410. Goncalves S, Moreira E, Grosso C, Andrade PB, Valentao P, Romano A. Phenolic profile, antioxidant activity and enzyme inhibitory activities of extracts from aromatic plants used in Mediterranean diet. J Food Sci Technol. 2017;54(1):219-227.
  411. Nabavi SF, Tenore GC, Daglia M, Tundis R, Loizzo MR, Nabavi SM. The cellular protective effects of rosmarinic acid: from bench to bedside. Curr Neurovasc Res. 2015;12(1):98-105.
  412. Lee AY, Hwang BR, Lee MH, Lee S, Cho EJ. Perilla frutescens var. japonica and rosmarinic acid improve amyloid-beta25-35 induced impairment of cognition and memory function. Nutrition research and practice. 2016;10(3):274-281.
  413. Paudel P, Seong SH, Zhou Y, et al. Rosmarinic Acid Derivatives' Inhibition of Glycogen Synthase Kinase-3beta Is the Pharmacological Basis of Kangen-Karyu in Alzheimer's Disease. Molecules (Basel, Switzerland). 2018;23(11).
  414. Herrlinger KA, Nieman KM, Sanoshy KD, et al. Spearmint Extract Improves Working Memory in Men and Women with Age-Associated Memory Impairment. Journal of alternative and complementary medicine (New York, NY). 2018;24(1):37-47.
  415. Nieman KM. Tolerance, bioavailability, and potential cognitive health implications of a distinct aqueous spearmint extract. Functional Foods in Health and Disease. 2015;5(5):165–187.
  416. Wong RH, Howe PR, Bryan J, Coates AM, Buckley JD, Berry NM. Chronic effects of a wild green oat extract supplementation on cognitive performance in older adults: a randomised, double-blind, placebo-controlled, crossover trial. Nutrients. 2012;4(5):331-342.
  417. Dimpfel W, Storni C, Verbruggen M. Ingested oat herb extract (Avena sativa) changes EEG spectral frequencies in healthy subjects. Journal of alternative and complementary medicine (New York, NY). 2011;17(5):427-434.
  418. Maggiorani D, Manzella N, Edmondson DE, et al. Monoamine Oxidases, Oxidative Stress, and Altered Mitochondrial Dynamics in Cardiac Ageing. Oxid Med Cell Longev. 2017;2017:3017947.
  419. Weinreb O, Amit T, Bar-Am O, Youdim MB. Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and beta-amyloid in ageing and Alzheimer's disease. Br J Pharmacol. 2016;173(13):2080-2094.
  420. Riederer P, Muller T. Use of monoamine oxidase inhibitors in chronic neurodegeneration. Expert opinion on drug metabolism & toxicology. 2017;13(2):233-240.
  421. Perrinjaquet-Moccetti T, Wullschleger C, Schmidt A, Aydogan C, Kreuter M. Bioactivity-based development of a wild green oat (Avena sativa L.) extract in support of mental health disorders. Vol 272006.
  422. Garcia AM, Martinez A, Gil C. Enhancing cAMP Levels as Strategy for the Treatment of Neuropsychiatric Disorders. Current topics in medicinal chemistry. 2016;16(29):3527-3535.
  423. Heckman PRA, Blokland A, Prickaerts J. From Age-Related Cognitive Decline to Alzheimer's Disease: A Translational Overview of the Potential Role for Phosphodiesterases. Advances in neurobiology. 2017;17:135-168.
  424. Wong RH, Howe PR, Coates AM, Buckley JD, Berry NM. Chronic consumption of a wild green oat extract (Neuravena) improves brachial flow-mediated dilatation and cerebrovascular responsiveness in older adults. Journal of hypertension. 2013;31(1):192-200.
  425. Kennedy DO, Jackson PA, Forster J, et al. Acute effects of a wild green-oat (Avena sativa) extract on cognitive function in middle-aged adults: A double-blind, placebo-controlled, within-subjects trial. Nutritional neuroscience. 2017;20(2):135-151.
  426. Berry NM, Robinson MJ, Bryan J, Buckley JD, Murphy KJ, Howe PR. Acute effects of an Avena sativa herb extract on responses to the Stroop Color-Word test. Journal of alternative and complementary medicine (New York, NY). 2011;17(7):635-637.
  427. Friedman M. Chemistry, Nutrition, and Health-Promoting Properties of Hericium erinaceus (Lion's Mane) Mushroom Fruiting Bodies and Mycelia and Their Bioactive Compounds. J Agric Food Chem. 2015;63(32):7108-7123.
  428. Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res. 2009;23(3):367-372.
  429. Brandalise F, Cesaroni V, Gregori A, et al. Dietary Supplementation of Hericium erinaceus Increases Mossy Fiber-CA3 Hippocampal Neurotransmission and Recognition Memory in Wild-Type Mice. Evidence-based complementary and alternative medicine : eCAM. 2017;2017:3864340.
  430. Tsai-Teng T, Chin-Chu C, Li-Ya L, et al. Erinacine A-enriched Hericium erinaceus mycelium ameliorates Alzheimer's disease-related pathologies in APPswe/PS1dE9 transgenic mice. J Biomed Sci. 2016;23(1):49.
  431. Mori K, Obara Y, Moriya T, Inatomi S, Nakahata N. Effects of Hericium erinaceus on amyloid beta(25-35) peptide-induced learning and memory deficits in mice. Biomedical research (Tokyo, Japan). 2011;32(1):67-72.
  432. Misra HS, Rajpurohit YS, Khairnar NP. Pyrroloquinoline-quinone and its versatile roles in biological processes. Journal of biosciences. 2012;37(2):313-325.
  433. Rucker R, Chowanadisai W, Nakano M. Potential physiological importance of pyrroloquinoline quinone. Alternative medicine review : a journal of clinical therapeutic. 2009;14(3):268-277.
  434. Harris CB, Chowanadisai W, Mishchuk DO, Satre MA, Slupsky CM, Rucker RB. Dietary pyrroloquinoline quinone (PQQ) alters indicators of inflammation and mitochondrial-related metabolism in human subjects. J Nutr Biochem. 2013;24(12):2076-2084.
  435. Zhou XQ, Yao ZW, Peng Y, et al. PQQ ameliorates D-galactose induced cognitive impairments by reducing glutamate neurotoxicity via the GSK-3beta/Akt signaling pathway in mouse. Sci Rep. 2018;8(1):8894.
  436. Qin J, Wu M, Yu S, et al. Pyrroloquinoline quinone-conferred neuroprotection in rotenone models of Parkinson's disease. Toxicol Lett. 2015;238(3):70-82.
  437. Yang C, Yu L, Kong L, et al. Pyrroloquinoline quinone (PQQ) inhibits lipopolysaccharide induced inflammation in part via downregulated NF-kappaB and p38/JNK activation in microglial and attenuates microglia activation in lipopolysaccharide treatment mice. PLoS One. 2014;9(10):e109502.
  438. Guan S, Xu J, Guo Y, et al. Pyrroloquinoline quinone against glutamate-induced neurotoxicity in cultured neural stem and progenitor cells. International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience. 2015;42:37-45.
  439. Zhang Q, Chen S, Yu S, et al. Neuroprotective effects of pyrroloquinoline quinone against rotenone injury in primary cultured midbrain neurons and in a rat model of Parkinson's disease. Neuropharmacology. 2016;108:238-251.
  440. Kim J, Harada R, Kobayashi M, Kobayashi N, Sode K. The inhibitory effect of pyrroloquinoline quinone on the amyloid formation and cytotoxicity of truncated alpha-synuclein. Molecular neurodegeneration. 2010;5:20.
  441. Kim J, Kobayashi M, Fukuda M, et al. Pyrroloquinoline quinone inhibits the fibrillation of amyloid proteins. Prion. 2010;4(1):26-31.
  442. Kobayashi M, Kim J, Kobayashi N, et al. Pyrroloquinoline quinone (PQQ) prevents fibril formation of alpha-synuclein. Biochemical and biophysical research communications. 2006;349(3):1139-1144.
  443. Zhang JJ, Zhang RF, Meng XK. Protective effect of pyrroloquinoline quinone against Abeta-induced neurotoxicity in human neuroblastoma SH-SY5Y cells. Neurosci Lett. 2009;464(3):165-169.
  444. Yamaguchi K, Sasano A, Urakami T, Tsuji T, Kondo K. Stimulation of nerve growth factor production by pyrroloquinoline quinone and its derivatives in vitro and in vivo. Bioscience, biotechnology, and biochemistry. 1993;57(7):1231-1233.
  445. Urakami T, Tanaka A, Yamaguchi K, Tsuji T, Niki E. Synthesis of esters of coenzyme PQQ and IPQ, and stimulation of nerve growth factor production. BioFactors (Oxford, England). 1995;5(3):139-146.
  446. Murase K, Hattori A, Kohno M, Hayashi K. Stimulation of nerve growth factor synthesis/secretion in mouse astroglial cells by coenzymes. Biochemistry and molecular biology international. 1993;30(4):615-621.
  447. Liu S, Li H, Ou Yang J, et al. Enhanced rat sciatic nerve regeneration through silicon tubes filled with pyrroloquinoline quinone. Microsurgery. 2005;25(4):329-337.
  448. Li HH, Liu SQ, Peng H, Zhang N. Pyrroloquinoline quinone enhances regeneration of transected sciatic nerve in rats. Chinese journal of traumatology = Zhonghua chuang shang za zhi / Chinese Medical Association. 2005;8(4):225-229.
  449. Ohwada K, Takeda H, Yamazaki M, et al. Pyrroloquinoline Quinone (PQQ) Prevents Cognitive Deficit Caused by Oxidative Stress in Rats. Journal of clinical biochemistry and nutrition. 2008;42:29-34.
  450. Itoh Y, Hine K, Miura H, et al. Effect of the Antioxidant Supplement Pyrroloquinoline Quinone Disodium Salt (BioPQQ) on Cognitive Functions. Adv Exp Med Biol. 2016;876:319-325.
  451. Nakano M, Murayama Y, Hu L, Ikemoto K, Uetake T, Sakatani K. Effects of Antioxidant Supplements (BioPQQ) on Cerebral Blood Flow and Oxygen Metabolism in the Prefrontal Cortex. Adv Exp Med Biol. 2016;923:215-222.
  452. Srivastava S. Emerging therapeutic roles for NAD(+) metabolism in mitochondrial and age-related disorders. Clinical and translational medicine. 2016;5(1):25.
  453. Stein LR, Imai S. The dynamic regulation of NAD metabolism in mitochondria. Trends in endocrinology and metabolism: TEM. 2012;23(9):420-428.
  454. Mendelsohn AR, Larrick JW. The NAD+/PARP1/SIRT1 Axis in Aging. Rejuvenation research. 2017;20(3):244-247.
  455. Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464-471.
  456. Kulikova V, Shabalin K, Nerinovski K, et al. Generation, Release, and Uptake of the NAD Precursor Nicotinic Acid Riboside by Human Cells. The Journal of biological chemistry. 2015;290(45):27124-27137.
  457. Yang Y, Sauve AA. NAD(+) metabolism: Bioenergetics, signaling and manipulation for therapy. Biochim Biophys Acta. 2016;1864(12):1787-1800.
  458. Elhassan YS, Philp AA, Lavery GG. Targeting NAD+ in Metabolic Disease: New Insights Into an Old Molecule. Journal of the Endocrine Society. 2017;1(7):816-835.
  459. Matasic DS, Brenner C, London B. Emerging potential benefits of modulating NAD(+) metabolism in cardiovascular disease. American journal of physiology Heart and circulatory physiology. 2018;314(4):H839-h852.
  460. Yoshino J, Baur JA, Imai SI. NAD(+) Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell metabolism. 2018;27(3):513-528.
  461. Dellinger RW, Santos SR, Morris M, et al. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD(+) levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. NPJ aging and mechanisms of disease. 2017;3:17.
  462. Gong B, Pan Y, Vempati P, et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol Aging. 2013;34(6):1581-1588.
  463. Hou Y, Lautrup S, Cordonnier S, et al. NAD(+) supplementation normalizes key Alzheimer's features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency. Proceedings of the National Academy of Sciences of the United States of America. 2018;115(8):E1876-e1885.
  464. Zhang H, Ryu D, Wu Y, et al. NAD(+) repletion improves mitochondrial and stem cell function and enhances life span in mice. Science (New York, NY). 2016;352(6292):1436-1443.
  465. Khan NA, Auranen M, Paetau I, et al. Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3. EMBO molecular medicine. 2014;6(6):721-731.
  466. Singh A, Kumar A. Microglial Inhibitory Mechanism of Coenzyme Q10 Against Abeta (1-42) Induced Cognitive Dysfunctions: Possible Behavioral, Biochemical, Cellular, and Histopathological Alterations. Frontiers in pharmacology. 2015;6:268.
  467. Bhardwaj M, Kumar A. Neuroprotective mechanism of Coenzyme Q10 (CoQ10) against PTZ induced kindling and associated cognitive dysfunction: Possible role of microglia inhibition. Pharmacological reports : PR. 2016;68(6):1301-1311.
  468. Yamagishi K, Ikeda A, Moriyama Y, et al. Serum coenzyme Q10 and risk of disabling dementia: the Circulatory Risk in Communities Study (CIRCS). Atherosclerosis. 2014;237(2):400-403.
  469. Kure CE, Rosenfeldt FL, Scholey AB, et al. Relationships Among Cognitive Function and Cerebral Blood Flow, Oxidative Stress, and Inflammation in Older Heart Failure Patients. Journal of cardiac failure. 2016;22(7):548-559.
  470. Li Z, Wang P, Yu Z, et al. The effect of creatine and coenzyme q10 combination therapy on mild cognitive impairment in Parkinson's disease. European neurology. 2015;73(3-4):205-211.
  471. Dumont M, Kipiani K, Yu F, et al. Coenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis. 2011;27(1):211-223.
  472. Hickey MA, Zhu C, Medvedeva V, Franich NR, Levine MS, Chesselet MF. Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease. Molecular and cellular neurosciences. 2012;49(2):149-157.